Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2015

Aug 20, 2015

30016_dirs_2015-08-20_a3dae810-95d9-468b-9eca-5d89f6bee0e4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2015-08-18

Reporting Person: Williams Michael J PhD (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-08-18 Common Stock M 6586 $26.66 Acquired 36672 Direct
2015-08-18 Common Stock S 6586 $78.34 Disposed 30086 Direct
2015-08-18 Common Stock M 3750 $26.66 Acquired 33836 Direct
2015-08-18 Common Stock M 5818 $17.19 Acquired 39654 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-08-18 Non-Qualified Stock Option (Right to buy) $26.66 M 6586 Disposed 2017-02-13 Common Stock (6586) Direct
2015-08-18 Incentive Stock Option (Right to buy) $26.66 M 3750 Disposed 2017-02-13 Common Stock (3750) Direct
2015-08-18 Incentive Stock Option (Right to buy) $17.19 M 5818 Disposed 2016-02-13 Common Stock (5818) Direct

Footnotes

F1: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $78.33 to $78.40, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

F2: Grant of option to buy shares of IDEXX Laboratories Inc. common stock that became exercisable as to 3,834 shares on 2/14/2011, 2/14/2012, 2/14/2013 and 2/14/2014 and the remaining 1,959 shares on 2/14/2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F3: Grant of option to buy 1,875 shares of IDEXX Laboratories, Inc. common stock that became exercisable on the fifth anniversary date (2/14/2015) of the date of grant, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F4: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 1 share on 02/14/2010 and 02/14/2013 and the remaining 2,909 shares on 02/14/2014, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.